Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Patterson JR, Duffy MF, Kemp CJ, Howe JW, Collier TJ, Stoll AC, Miller KM, Patel P, Levine N, Moore DJ, Luk KC, Fleming SM, Kanaan NM, Paumier KL, El-Agnaf OMA, Sortwell CE.

Neurobiol Dis. 2019 Jul 2;130:104525. doi: 10.1016/j.nbd.2019.104525. [Epub ahead of print]

2.

Parkinson's Disease Biomarkers based on Alpha-synuclein.

Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, El-Agnaf OMA.

J Neurochem. 2019 Jul 2. doi: 10.1111/jnc.14809. [Epub ahead of print] Review.

PMID:
31265130
3.

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy.

Wu JZ, Ardah M, Haikal C, Svanbergsson A, Diepenbroek M, Vaikath NN, Li W, Wang ZY, Outeiro TF, El-Agnaf OM, Li JY.

Transl Neurodegener. 2019 Jun 15;8:18. doi: 10.1186/s40035-019-0159-7. eCollection 2019.

4.

Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.

Murakami H, Tokuda T, El-Agnaf OMA, Ohmichi T, Miki A, Ohashi H, Owan Y, Saito Y, Yano S, Tsukie T, Ikeuchi T, Ono K.

BMC Neurol. 2019 Jun 4;19(1):113. doi: 10.1186/s12883-019-1346-y.

5.

Antibodies against alpha-synuclein: tools and therapies.

Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA.

J Neurochem. 2019 May 4. doi: 10.1111/jnc.14713. [Epub ahead of print] Review.

PMID:
31055836
6.

Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid.

Kakuda K, Ikenaka K, Araki K, So M, Aguirre C, Kajiyama Y, Konaka K, Noi K, Baba K, Tsuda H, Nagano S, Ohmichi T, Nagai Y, Tokuda T, El-Agnaf OMA, Ogi H, Goto Y, Mochizuki H.

Sci Rep. 2019 Apr 12;9(1):6001. doi: 10.1038/s41598-019-42399-0.

7.

Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.

Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M, Paciotti S, Quiroga-Varela A, Chiasserini D, Mellone M, Mazzocchetti P, Calabrese V, Campanelli F, Mechelli A, Di Filippo M, Ghiglieri V, Picconi B, El-Agnaf OM, De Leonibus E, Gardoni F, Tozzi A, Calabresi P.

Brain. 2019 May 1;142(5):1365-1385. doi: 10.1093/brain/awz065.

8.

Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Spencer B, Trinh I, Rockenstein E, Mante M, Florio J, Adame A, El-Agnaf OMA, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.

PMID:
30849508
9.

α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.

van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA.

Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15. Erratum in: Mov Disord. 2019 Jan;34(1):159.

10.

Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.

Vaikath NN, Erskine D, Morris CM, Majbour NK, Vekrellis K, Li JY, El-Agnaf OMA.

Neuropathol Appl Neurobiol. 2018 Nov 13. doi: 10.1111/nan.12531. [Epub ahead of print]

PMID:
30422353
11.

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 29;15(1):169. doi: 10.1186/s12974-018-1202-9.

12.

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.

Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, Paumier KL, Kanaan NM, Fischer DL, Polinski NK, Barth OL, Howe JW, Vaikath NN, Majbour NK, El-Agnaf OMA, Sortwell CE.

J Neuroinflammation. 2018 May 1;15(1):129. doi: 10.1186/s12974-018-1171-z. Erratum in: J Neuroinflammation. 2018 May 29;15(1):169.

13.

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice.

Karampetsou M, Ardah MT, Semitekolou M, Polissidis A, Samiotaki M, Kalomoiri M, Majbour N, Xanthou G, El-Agnaf OMA, Vekrellis K.

Sci Rep. 2017 Nov 28;7(1):16533. doi: 10.1038/s41598-017-15813-8.

14.

Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism?

Sakaue S, Kasai T, Mizuta I, Suematsu M, Osone S, Azuma Y, Imamura T, Tokuda T, Kanno H, El-Agnaf OMA, Morimoto M, Nakagawa M, Hosoi H, Mizuno T.

NPJ Parkinsons Dis. 2017 Mar 31;3:13. doi: 10.1038/s41531-017-0014-4. eCollection 2017.

15.

Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.

Kruse N, El-Agnaf OM, Mollenhauer B.

Bioanalysis. 2017 Apr;9(8):621-630. doi: 10.4155/bio-2017-0005. Epub 2017 May 15.

PMID:
28504552
16.

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects.

Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, Nguyen AP, Cron GO, Jiang Q, Roberson ED, Nussbaum RL, Majbour NK, El-Agnaf OM, Bennett SA, Lagace DC, Woulfe JM, Sad S, Brown EG, Schlossmacher MG.

J Neural Transm (Vienna). 2017 Jun;124(6):721-738. doi: 10.1007/s00702-017-1726-7. Epub 2017 May 5.

17.

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease.

Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W, Parnetti L, Calabresi P, El-Agnaf OM.

Sci Rep. 2017 Jan 10;7:40263. doi: 10.1038/srep40263.

18.

Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum.

Sharrad DF, Chen BN, Gai WP, Vaikath N, El-Agnaf OM, Brookes SJ.

Neurogastroenterol Motil. 2017 Apr;29(4). doi: 10.1111/nmo.12985. Epub 2016 Nov 7.

PMID:
27997067
19.

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.

Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik D.

Mol Neurodegener. 2016 Aug 22;11(1):61. doi: 10.1186/s13024-016-0125-0.

20.

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.

Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah M, Varghese S, Haque ME, Tokuda T, Auinger P, Calabresi P, Parnetti L, El-Agnaf OM.

Mov Disord. 2016 Oct;31(10):1535-1542. doi: 10.1002/mds.26754.

PMID:
27548849
21.

Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function.

Kim DK, Lim HS, Kawasaki I, Shim YH, Vaikath NN, El-Agnaf OM, Lee HJ, Lee SJ.

Autophagy. 2016 Oct 2;12(10):1849-1863. Epub 2016 Aug 2.

22.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

23.

Glycation in Parkinson's disease and Alzheimer's disease.

Vicente Miranda H, El-Agnaf OM, Outeiro TF.

Mov Disord. 2016 Jun;31(6):782-90. doi: 10.1002/mds.26566. Epub 2016 Mar 4. Review.

PMID:
26946341
24.

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.

Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, Montezinho LP, Poole S, Safieh-Garabedian B, Tokuda T, Teunissen CE, Berendse HW, van de Berg WD, El-Agnaf OM.

Mol Neurodegener. 2016 Jan 19;11:7. doi: 10.1186/s13024-016-0072-9.

25.

Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice.

Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OM, Ulusoy A, Di Monte DA.

Brain. 2016 Mar;139(Pt 3):856-70. doi: 10.1093/brain/awv376. Epub 2015 Dec 30.

PMID:
26719384
26.

Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders.

Javed H, Menon SA, Al-Mansoori KM, Al-Wandi A, Majbour NK, Ardah MT, Varghese S, Vaikath NN, Haque ME, Azzouz M, El-Agnaf OM.

Mol Ther. 2016 Apr;24(4):746-58. doi: 10.1038/mt.2015.232. Epub 2015 Dec 24. Erratum in: Mol Ther. 2016 Apr;24(4):843.

27.

Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit.

Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di Filippo M, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampà C, Dalley JW, Xia J, Gardoni F, Mellone M, El-Agnaf OM, Ardah MT, Puglisi-Allegra S, Björklund A, Spillantini MG, Picconi B, Calabresi P.

Biol Psychiatry. 2016 Mar 1;79(5):402-414. doi: 10.1016/j.biopsych.2015.08.013. Epub 2015 Aug 20.

PMID:
26392130
28.

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.

Simonsen AH, Kuiperij B, El-Agnaf OM, Engelborghs S, Herukka SK, Parnetti L, Rektorova I, Vanmechelen E, Kapaki E, Verbeek M, Mollenhauer B.

Biomark Med. 2016;10(1):19-34. doi: 10.2217/BMM.14.105. Epub 2015 Aug 28. Review.

PMID:
26314196
29.

Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.

Lawand NB, Saadé NE, El-Agnaf OM, Safieh-Garabedian B.

Expert Opin Ther Targets. 2015;19(10):1351-60. doi: 10.1517/14728222.2015.1062877. Epub 2015 Jul 1. Review.

PMID:
26135549
30.

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.

Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DM, Imai Y, Halliday GM, Li JY, El-Agnaf OM.

Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30.

PMID:
25937088
31.

Decrease in plasma levels of α-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference.

Ishii R, Tokuda T, Tatebe H, Ohmichi T, Kasai T, Nakagawa M, Mizuno T, El-Agnaf OM.

PLoS One. 2015 Apr 7;10(4):e0123162. doi: 10.1371/journal.pone.0123162. eCollection 2015.

32.

Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.

Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D.

Neurobiol Dis. 2015 Jun;78:100-14. doi: 10.1016/j.nbd.2015.03.008. Epub 2015 Mar 25.

PMID:
25818009
33.

Detection of oligomers and fibrils of α-synuclein by AIEgen with strong fluorescence.

Leung CW, Guo F, Hong Y, Zhao E, Kwok RT, Leung NL, Chen S, Vaikath NN, El-Agnaf OM, Tang Y, Gai WP, Tang BZ.

Chem Commun (Camb). 2015 Feb 4;51(10):1866-9. doi: 10.1039/c4cc07911f.

PMID:
25526628
34.

Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils.

Ardah MT, Paleologou KE, Lv G, Menon SA, Abul Khair SB, Lu JH, Safieh-Garabedian B, Al-Hayani AA, Eliezer D, Li M, El-Agnaf OM.

Neurobiol Dis. 2015 Feb;74:89-101. doi: 10.1016/j.nbd.2014.11.007. Epub 2014 Nov 15.

35.

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

Aasly JO, Johansen KK, Brønstad G, Warø BJ, Majbour NK, Varghese S, Alzahmi F, Paleologou KE, Amer DA, Al-Hayani A, El-Agnaf OM.

Front Aging Neurosci. 2014 Sep 25;6:248. doi: 10.3389/fnagi.2014.00248. eCollection 2014.

36.

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity.

Ardah MT, Paleologou KE, Lv G, Abul Khair SB, Kazim AS, Minhas ST, Al-Tel TH, Al-Hayani AA, Haque ME, Eliezer D, El-Agnaf OM.

Front Aging Neurosci. 2014 Aug 5;6:197. doi: 10.3389/fnagi.2014.00197. eCollection 2014.

37.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.

Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM.

Alzheimers Res Ther. 2014 May 7;6(3):25. doi: 10.1186/alzrt255. eCollection 2014.

38.

Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid.

Persichetti E, Chiasserini D, Parnetti L, Eusebi P, Paciotti S, De Carlo C, Codini M, Tambasco N, Rossi A, El-Agnaf OM, Calabresi P, Beccari T.

PLoS One. 2014 Jul 1;9(7):e101453. doi: 10.1371/journal.pone.0101453. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e114809. El Agnaf, Omar M [corrected to El-Agnaf, Omar M A].

39.

Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Kasai T, Tokuda T, Ishii R, Ishigami N, Tsuboi Y, Nakagawa M, Mizuno T, El-Agnaf OM.

J Neurol. 2014 Jun;261(6):1203-9. doi: 10.1007/s00415-014-7334-7. Epub 2014 Apr 16.

PMID:
24737170
40.

The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.

Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, Paunovic V, Ardah MT, El-Agnaf OM, Kostic V, Markovic I, Trajkovic V.

Neurobiol Dis. 2014 Mar;63:1-11. doi: 10.1016/j.nbd.2013.11.002. Epub 2013 Nov 20.

PMID:
24269733
41.

The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.

Al-Mansoori KM, Hasan MY, Al-Hayani A, El-Agnaf OM.

Curr Alzheimer Res. 2013 Jul;10(6):559-68. Review.

PMID:
23899170
42.

Involvement of the α7-nicotinic acetylcholine receptors in the anti-inflammatory action of the thymulin-related peptide (PAT).

Safieh-Garabedian B, Oz M, Bey RM, Shamaa F, Ashoor A, El-Agnaf OM, Saadé NE.

Neuroscience. 2013 Oct 10;250:455-66. doi: 10.1016/j.neuroscience.2013.07.031. Epub 2013 Jul 21.

PMID:
23880090
43.

Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers.

Gorostidi A, Bergareche A, Ruiz-Martínez J, Martí-Massó JF, Cruz M, Varghese S, Qureshi MM, Alzahmi F, Al-Hayani A, López de Munáin A, El-Agnaf OM.

PLoS One. 2012;7(12):e52312. doi: 10.1371/journal.pone.0052312. Epub 2012 Dec 27.

44.

α-Synuclein aggregation and modulating factors.

Paleologou KE, El-Agnaf OM.

Subcell Biochem. 2012;65:109-64. doi: 10.1007/978-94-007-5416-4_6. Review.

PMID:
23225002
45.

The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms.

O'Dowd ST, Ardah MT, Johansson P, Lomakin A, Benedek GB, Roberts KA, Cummins G, El Agnaf OM, Svensson J, Zetterberg H, Lynch T, Walsh DM.

J Alzheimers Dis. 2013;33(4):923-8. doi: 10.3233/JAD-2012-121393.

PMID:
23034520
46.

Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.

Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL.

Acta Neuropathol. 2012 May;123(5):653-69. doi: 10.1007/s00401-012-0963-y. Epub 2012 Feb 24.

PMID:
22361813
47.

α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer.

Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, Lashuel HA.

J Biol Chem. 2012 May 4;287(19):15345-64. doi: 10.1074/jbc.M111.318949. Epub 2012 Feb 7.

48.

Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.

Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM.

Neuroscience. 2011 Dec 29;199:303-17. doi: 10.1016/j.neuroscience.2011.10.018. Epub 2011 Oct 20.

PMID:
22056602
49.

S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer's type.

Javed H, Khan MM, Khan A, Vaibhav K, Ahmad A, Khuwaja G, Ahmed ME, Raza SS, Ashafaq M, Tabassum R, Siddiqui MS, El-Agnaf OM, Safhi MM, Islam F.

Brain Res. 2011 May 10;1389:133-42. doi: 10.1016/j.brainres.2011.02.072. Epub 2011 Mar 1.

PMID:
21376020
50.

Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.

Lu JH, Ardah MT, Durairajan SS, Liu LF, Xie LX, Fong WF, Hasan MY, Huang JD, El-Agnaf OM, Li M.

Chembiochem. 2011 Mar 7;12(4):615-24. doi: 10.1002/cbic.201000604. Epub 2011 Jan 26.

PMID:
21271629

Supplemental Content

Loading ...
Support Center